Search Details

Word: profit (lookup in dictionary) (lookup stats)
Dates: all
Sort By: most recent first (reverse)


Usage:

...risk life and liberty for riches they could never hope to acquire in a lifetime of work in the legitimate economy. And the same may be true for the young men willing to risk lengthy prison terms to sell it on the streets of America's cities. The profit margins involved certainly make narco-trafficking a lucrative proposition for criminal entrepreneurs, despite the fact that the U.N. claims that almost half of all cocaine shipped to market is intercepted...

Author: /time Magazine | Title: Peru Plane Tragedy Highlights a Troubled War on Drugs | 4/24/2001 | See Source »

...Syrians Profit by Old Neckties, Two Bibles and an Inner Tube...

Author: NO WRITER ATTRIBUTED | Title: Crimson History | 4/23/2001 | See Source »

...theirs to mess up," says Larry Feinberg, health-care hedge-fund manager at Oracle Partners. WebMD lost $246 million last year, despite more than doubling revenues, to $517 million. But the loss was smaller than anticipated, and it expects to turn a profit later this year. To compete with Allscripts and other e-scription players, Wygod is racing to roll out his own portable platform. He just inked a deal to be the primary content provider for Microsoft's MSN service...

Author: /time Magazine | Title: To The Rescue! | 4/23/2001 | See Source »

...more Prozac (Eli Lilly). These stocks aren't immune to the broader market's misfortune. The American Stock Exchange Pharmaceutical Index has fallen 12.8% since Jan. 2, while Standard & Poor's 500 is down 8.4%. But drug stocks offer something that has been scarce in this environment--profit growth...

Author: /time Magazine | Title: Prescription For The Dow? | 4/23/2001 | See Source »

...consensus among drug analysts is that Pfizer will report the highest profit growth for the quarter, up 24% over the same period a year ago. "It's the best of all the drug companies," says portfolio manager David Alger, who owns about $300 million worth of Pfizer in his funds. Merrill Lynch analyst Steve Tighe is high on the new products coming from Pharmacia, which has partnered with Pfizer to launch a new anti-arthritis drug. And he says Elan is attractive since it trades at a discount to large cap and specialty-drug stocks...

Author: /time Magazine | Title: Prescription For The Dow? | 4/23/2001 | See Source »

Previous | 591 | 592 | 593 | 594 | 595 | 596 | 597 | 598 | 599 | 600 | 601 | 602 | 603 | 604 | 605 | 606 | 607 | 608 | 609 | 610 | 611 | Next